Daxor Corp (DXR)

May 14, 2025, 8:00 AM EDT - 22 days ago

Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal

May 13, 2025, 8:00 AM EDT - 23 days ago

Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems

May 7, 2025, 8:00 AM EDT - 4 weeks ago

Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology

May 6, 2025, 8:00 AM EDT - 4 weeks ago

Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance

Apr 22, 2025, 8:00 AM EDT - 6 weeks ago

Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions

Apr 17, 2025, 8:00 AM EDT - 7 weeks ago

Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025

Apr 15, 2025, 8:00 AM EDT - 7 weeks ago

New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival

Apr 2, 2025, 8:00 AM EDT - 2 months ago

Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo

Mar 28, 2025, 8:00 AM EDT - 2 months ago

Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks

Mar 6, 2025, 9:00 PM EST - 3 months ago

Daxor Corporation (DXR) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 4:55 PM EST - 3 months ago

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

Mar 4, 2025, 3:53 PM EST - 3 months ago

Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

Mar 4, 2025, 9:00 AM EST - 3 months ago

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Mar 4, 2025, 8:00 AM EST - 3 months ago

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

Feb 28, 2025, 8:00 AM EST - 3 months ago

Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center

Feb 27, 2025, 8:00 AM EST - 3 months ago

Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals

Feb 19, 2025, 8:00 AM EST - 3 months ago

Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025

Feb 18, 2025, 10:50 AM EST - 3 months ago

TruLite Health Bolsters Health Equity Expertise with Expanded Leadership Team

ARDT

Feb 18, 2025, 8:00 AM EST - 3 months ago

Daxor to Exhibit at World's Largest Critical Care Conference

Feb 14, 2025, 8:00 AM EST - 3 months ago

Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment

Feb 13, 2025, 8:00 AM EST - 4 months ago

New Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care

Dec 18, 2024, 8:00 AM EST - 6 months ago

Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum

Oct 9, 2024, 8:00 AM EDT - 8 months ago

DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24

Oct 8, 2024, 8:00 AM EDT - 8 months ago

Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Sep 27, 2024, 5:00 PM EDT - 8 months ago

Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device

Sep 19, 2024, 8:00 AM EDT - 9 months ago

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024

Sep 4, 2024, 8:30 AM EDT - 9 months ago

Leading Central Florida Hospital Implements Daxor's BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care

Sep 3, 2024, 4:05 PM EDT - 9 months ago

Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter

Sep 3, 2024, 12:15 PM EDT - 9 months ago

Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 8:00 AM EDT - 10 months ago

Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network

Aug 5, 2024, 8:00 AM EDT - 10 months ago

Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide

Jun 18, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital

Mar 25, 2024, 8:05 PM EDT - 1 year ago

Daxor Corporation (DXR) Q4 2023 Earnings Call Transcript

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

Mar 22, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024

Mar 18, 2024, 2:18 PM EDT - 1 year ago

Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base

Mar 8, 2024, 8:00 AM EST - 1 year ago

Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients

Feb 26, 2024, 8:00 AM EST - 1 year ago

Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference

Feb 12, 2024, 8:00 AM EST - 1 year ago

Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions

Jan 2, 2024, 8:30 AM EST - 1 year ago

Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer

Nov 13, 2023, 8:00 AM EST - 1 year ago

New Randomized Controlled Trial Demonstrates the Efficacy of Daxor's BVA Guided-Care in Heart Failure Patients

Oct 13, 2023, 8:00 AM EDT - 1 year ago

Expert Panelists Advocate Use of Daxor's Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting

Oct 11, 2023, 8:00 AM EDT - 1 year ago

New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100® Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting

Oct 4, 2023, 8:00 AM EDT - 1 year ago

Daxor Corporation Awarded Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program

Sep 27, 2023, 8:00 AM EDT - 1 year ago

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023

Sep 11, 2023, 12:00 PM EDT - 1 year ago

Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients

Sep 7, 2023, 9:15 AM EDT - 1 year ago

Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 28, 2023, 4:05 PM EDT - 1 year ago

Daxor Corporation Reports a 20.64 Percent Increase in Diagnostic Test Kits Revenue From Prior Year Period in Form N-CSR Filing for the Six Months Ended June 30, 2023